Table 3

Prostate cancer incidence by dietary calcium intake CPS-II Nutrition Cohort, 1992–1999a

Dietary calcium intake (mg/day)Prostate cancer casesPerson-yearsRR (95% CI)bRR (95% CI)cRR (95% CI)d
Total prostate cancer cases
 <7001454162,387111
 700–9991200125,6821.0 (0.9–1.1)1.0 (0.9–1.1)1.0 (0.9–1.1)
 1000–149963267,5201.0 (0.9–1.1)1.0 (0.9–1.0)1.0 (0.9–1.2)
 1500–199913012,8331.0 (0.9–1.2)1.0 (0.8–1.2)1.1 (0.9–1.5)
 ≥2000422,8321.5 (1.1–2.0)1.4 (1.1–2.0)1.6 (1.1–2.3)
P trend = 0.52P trend = 0.76P trend = 0.10
Advanced prostate cancer cases
 <700247154,547111
 700–999149118,8910.8 (0.6–0.9)0.8 (0.6–0.9)0.8 (0.6–1.9)
 1000–14999964,0830.9 (0.7–1.2)0.9 (0.7–1.2)1.1 (0.7–1.7)
 1500–19991912,1100.9 (0.6–1.5)0.9 (0.6–1.5)1.2 (0.6–2.4)
 ≥200082,6081.8 (0.9–3.6)1.7 (0.8–3.5)2.2 (0.9–5.3)
P trend = 0.95P trend = 0.95P trend = 0.27
  • a Excludes 353 prostate cancer cases and 5079 noncases taking individual calcium supplements.

  • b Adjusted for age at entry and race.

  • c Adjusted for age at entry, race, family history of prostate cancer, total energy, total fat intake, and education.

  • d Adjusted for age at entry, race, family history of prostate cancer, total energy, total fat intake, education, phosphorus and total vitamin D.